Research.Patient.info
Focal segmental glomerulosclerosis (FSGS) research hub
2 indexed studies · 1 currently recruiting
- authorisedPhase II and Phase III (Integrated)
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
This clinical trial is testing a medicine called pegcetacoplan for people with focal segmental glomerulosclerosis (FSGS), a rare kidney condition. Researchers want to see if the treatment safely reduces the amount of protein leaking into the urine and helps protect kidney function over time.
France · Portugal · Spain - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
Germany · Belgium · France